Independent · non-commercial · publishes on a quarterly cycle|Current cycle 2026 Q3
Methodology|Interests|Funding|Corrections
Compound Evidence InstituteEvidence synthesis · established 2023Graded assessments of compounds, trials, methods and supply
Document set current to 30 July 2026
Document series

Trial abstracts — page 30

700 structured trial abstracts. Each is one document in five parts: abstract, design and population, results, certainty assessment and citing documents.

Showing 0 records on this page

Trial records

700 documents · page 30 of 30

Table 1. Trial records on this page. The table sorts on any column and filters on the controls above; both operate on the records shown on this page only.

RecordCompoundPhaseStatusDesignRandomisedYearCertainty
TRIUMPH-3-OLEprogramme recordRetatrutidePhase 3OngoingSingle-arm open-label——Very low
TRIUMPH-4-BODY-COMPprogramme recordRetatrutidePhase 3OngoingRandomised, double-blind, placebo-controlled——Very low
TRIUMPH-4-REGIONAL-JPprogramme recordRetatrutidePhase 3OngoingRandomised, double-blind, placebo-controlled——Very low
TRIUMPH-OSA-OLEprogramme recordRetatrutidePhase 3OngoingSingle-arm open-label——Very low

page 30 of 30

Nothing published by the Institute is medical advice, a diagnosis, a prescription, a treatment recommendation or a purchasing recommendation. Compounds supplied for research use are not approved for human or veterinary use in any jurisdiction, and a favourable analytical assessment of a supplier is not a statement that any product is safe or effective. The Institute publishes certainty ratings and never recommendations. No telephone number, messaging handle or ordering channel appears anywhere on this site.